Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
Category 1 Bulk Substances Peptides listed as Category 1 may be compounded by 503A pharmacies with a valid, patient-specific prescription while under FDA review
*Disclaimer: This product is intended solely for laboratory research purposes
Elsevier, pp 491552 Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT (2011) Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders
Legal Disclaimer This product is intended strictly for laboratory research purposes and is not approved for human or veterinary use
FX: Software, Writing original draft, Formal Analysis, Data curation